Loading...
XSHG
603456
Market cap2.40bUSD
Sep 22, Last price  
19.00CNY
1D
-2.71%
1Q
37.01%
Jan 2017
61.60%
IPO
185.13%
Name

Zhejiang Jiuzhou Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
27.64
P/S
3.25
EPS
0.69
Div Yield, %
2.58%
Shrs. gr., 5y
2.26%
Rev. gr., 5y
20.67%
Revenues
5.16b
-6.57%
590,669,767652,528,857833,378,939935,110,2281,143,419,7501,309,584,2041,286,206,7661,444,511,0851,653,177,2101,717,440,5991,862,225,1582,016,815,8532,647,284,1634,063,181,9155,445,105,1545,523,418,1755,160,584,725
Net income
606m
-41.34%
41,423,75267,211,243109,859,779117,049,728136,256,784166,240,814133,278,522200,079,304111,480,460147,605,263157,147,456237,793,378380,584,950633,900,939921,170,3701,033,255,687606,096,350
CFO
992m
-27.10%
82,841,684122,025,843105,299,432111,006,749154,281,690203,861,15310,167,664140,525,669136,646,433244,201,283264,782,500554,161,971400,392,398677,519,2361,225,782,0921,360,323,930991,655,174
Dividend
Jul 04, 20240.5 CNY/sh

Profile

Zhejiang Jiuzhou Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients (API) and intermediates in China and internationally. Its API pipeline comprise central nervous system, non-steroidal, anti-infection, hypoglycemic and antiviral, tumor treatment, anti-depressant, Parkinson, HCV drugs, diabetes, cardiovascular, and respiratory anti-infection drugs. The company also provides asymmetric catalysts and lithium battery materials. Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973 and is headquartered in Taizhou, China.
IPO date
Oct 10, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,160,585
-6.57%
5,523,418
1.44%
5,445,105
34.01%
Cost of revenue
3,899,578
4,017,233
3,999,154
Unusual Expense (Income)
NOPBT
1,261,006
1,506,185
1,445,952
NOPBT Margin
24.44%
27.27%
26.56%
Operating Taxes
123,535
149,270
183,272
Tax Rate
9.80%
9.91%
12.67%
NOPAT
1,137,471
1,356,915
1,262,680
Net income
606,096
-41.34%
1,033,256
12.17%
921,170
45.32%
Dividends
(471,296)
(358,649)
(208,575)
Dividend yield
3.84%
1.66%
0.59%
Proceeds from repurchase of equity
(130,348)
(65,287)
BB yield
1.06%
0.30%
Debt
Debt current
201,930
7,768
256,854
Long-term debt
210,307
412,839
105,187
Deferred revenue
139,892
109,116
101,196
Other long-term liabilities
41,765
50,767
25,757
Net debt
(2,336,635)
(2,907,698)
(848,509)
Cash flow
Cash from operating activities
991,655
1,360,324
1,225,782
CAPEX
(888,965)
(929,442)
Cash from investing activities
(881,326)
(1,056,803)
Cash from financing activities
(609,611)
2,102,185
FCF
572,962
174,268
862,927
Balance
Cash
2,748,871
3,206,427
1,095,426
Long term investments
121,877
115,124
Excess cash
2,490,842
3,052,133
938,295
Stockholders' equity
4,000,611
3,864,621
3,407,502
Invested Capital
6,704,605
6,049,532
4,806,061
ROIC
17.84%
25.00%
27.87%
ROCE
13.58%
16.37%
24.71%
EV
Common stock shares outstanding
898,107
890,738
829,660
Price
13.68
-43.49%
24.21
-42.94%
42.43
-24.58%
Market cap
12,286,101
-43.03%
21,564,759
-38.74%
35,202,459
-24.98%
EV
10,022,376
18,728,999
34,428,871
EBITDA
1,671,623
1,888,004
1,794,149
EV/EBITDA
6.00
9.92
19.19
Interest
20,731
25,208
22,376
Interest/NOPBT
1.64%
1.67%
1.55%